Benign prostatic hyperplasia
Conditions
Interventions
A monotherapy group, which continuously received 5 mg tadalafil daily for 8 weeks.
An add-on group, which received 5mg tadalafil daily and 50 mg mirabegron daily for 4 weeks after 5 mg tadalafil daily
Sponsors
Division of Urology, Department of Surgery, Tottori University Faculty of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: The study included men with benign prostatic hyperplasia. Inclusion criteria are total OABSS 3 or greater with urinary urgency at least once per week, IPSS question 7 score 2 or greater and age 50 years or greater.
Exclusion criteria
Exclusion criteria: Study exclusion criteria are post-void residual urine volume greater than 100 ml, acute urinary retention, neurogenic bladder dysfunction, severe bladder diverticulum or urethral stricture, urinary tract malignant disease, previous intrapelvic irradiation, renal or hepatic impairment, severe cardiac disease, or considered unsuitable for the trial by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overactive bladder symptom score (OABSS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of night urination International prostate symptom score Overactive bladder-questionnaire (OAB-q) Nocturia-quality of life (N-QOL) | — |
Countries
Japan
Contacts
Public ContactMasashi Honda
Department of Surgery, Tottori University Faculty of Medicine Dvision of Urology
Outcome results
None listed